Single-Cell BCR Sequencing for Rapid Monoclonal Antibody Discovery

Inquiry

Figure 1. Single-cell BCR sequencing workflow — from immunized B cells to paired VH-VL sequences and recombinant monoclonal antibody expression in approximately one week.

Summary

Antibody discovery has a speed problem. Traditional hybridoma-based screening takes months, loses rare clones during cell fusion, and — for non-mouse species like rabbit — lacks reliable fusion partners altogether. Single-cell BCR sequencing (scBCR-seq) changes the arithmetic: it captures paired heavy- and light-chain variable regions directly from individual B cells, preserves native chain pairing, and moves from sorted cells to expressed antibody in about one week. Huang et al. (2026) demonstrated the logic end-to-end: using scBCR-seq, the team identified 12 functional rabbit monoclonal antibodies against the small-molecule antibiotic monensin from just 15 candidate sequences — an 80% hit rate — and built a time-resolved fluorescence immunoassay that detects residues in under 10 minutes. This article explains what scBCR-seq captures that other methods miss, why it is particularly well-suited to rabbit monoclonal antibody development, and how to think about building a scBCR-seq-based antibody discovery project.

The timeline provided in this article is for reference purposes only. Actual project duration depends on factors such as sample type, project design, sequencing requirements, and downstream analysis complexity. Contact our experts to discuss your specific research needs and receive a customized project timeline.

Key Takeaways

• scBCR-seq preserves native heavy-light chain pairing, the single most important variable for functional antibody expression. Hybridoma methods can lose pairing information during fusion; phage display creates artificial pairings that may not exist in vivo.
• The timeline advantage is substantial. From fluorescence-activated cell sorting (FACS) of antigen-specific B cells to recombinant antibody expression takes approximately one week with scBCR-seq, compared to 4–8 weeks for hybridoma and 6–12 weeks for phage display campaigns.
• Rabbit monoclonal antibodies are an ideal match for scBCR-seq. Rabbits produce antibodies with picomolar-range affinities and broad epitope coverage via gene conversion in gut-associated lymphoid tissue, but traditional rabbit hybridoma is severely limited by the absence of stable rabbit myeloma fusion partners.
• scBCR-seq recovers clones that hybridoma misses entirely. In a landmark benchmarking study, scBCR-seq identified 710 additional candidate lineages from the same B-cell population that hybridoma screening recovered — while still capturing 81% of the hybridoma-identified clones.
• The technology is species-agnostic. scBCR-seq has been validated in mouse, rat, rabbit, and human B cells, making it applicable to antibody discovery programs regardless of host species.

Why Antibody Discovery Needs a Faster Path

The conventional route to a monoclonal antibody has not changed fundamentally in decades. Immunize an animal, harvest splenocytes, fuse them with a myeloma cell line, screen thousands of hybridoma clones by limiting dilution, and hope that a stable, high-affinity clone survives the process. The fusion step alone is a bottleneck: in mouse, fusion efficiency ranges from 0.001% to 0.01%, meaning the vast majority of B cells never become hybridomas. In rabbit, the situation is worse — there is no universally accepted rabbit myeloma fusion partner, making rabbit hybridoma generation inconsistent and often outright infeasible.

Phage display solved some of these problems by decoupling antibody expression from cell viability. But it introduced a different limitation: the heavy and light chains displayed on a phage particle are paired artificially during library construction. A high-affinity clone from a phage display screen may represent a combination of VH and VL that never existed in any B cell in vivo, and when expressed as a full IgG, the artificial pairing can reduce affinity or introduce aggregation.

Single-cell BCR sequencing operates on a different premise. Instead of forcing B cells to survive fusion or randomly pairing chains in a library, it reads the native VH-VL pair directly from each individual B cell. The cell provides the pairing — the sequencer provides the sequence.

What Single-Cell BCR Sequencing Captures

scBCR-seq begins where most antibody discovery campaigns already start: with an immunized animal. After the final boost, splenocytes or peripheral blood mononuclear cells are isolated. From this point, the workflow diverges sharply from traditional methods.

Antigen-specific enrichment. Rather than fusing the entire B-cell population, scBCR-seq workflows typically enrich for antigen-specific cells first. Fluorescence-activated cell sorting (FACS) using fluorescently labeled antigen identifies memory B cells and plasmablasts that bind the target. For rabbit samples — where established plasma cell surface markers are less available than in mouse or human — most workflows target memory B cells, which can be identified by surface IgG expression combined with antigen labeling. Magnetic bead-based negative selection offers an alternative when FACS is unavailable, enriching B cells by depleting non-B lineages.

Single-cell encapsulation and sequencing. Enriched B cells are loaded onto a microfluidic or microwell-based platform, where individual cells are partitioned into nanoliter-scale compartments. Inside each compartment, a single B cell is lysed, and its mRNA is captured — including the full-length VH and VL transcripts. Reverse transcription appends a cell-specific barcode to each cDNA molecule. After amplification and sequencing, every recovered VH-VL pair carries a cellular barcode that links the two chains to the same originating B cell. Throughput varies by platform but typically ranges from 2,000 to 10,000 cells per channel, with >90% paired-chain recovery rates.

From sequence to antibody. The paired VH and VL sequences are synthesized and cloned into IgG expression vectors — heavy and light chain separately — and co-transfected into HEK293 or CHO cells. Transient expression produces full IgG within days. In the Huang et al. 2026 study, the entire path from FACS sorting to purified recombinant rabbit IgG took one week. The sequences are sequence-defined from the outset, meaning there is no hybridoma to subclone and no risk of clone drift during expansion.

The Rabbit Monoclonal Antibody Advantage

Why rabbit? Three biological reasons make rabbit B cells a particularly productive source for scBCR-seq-based antibody discovery.

First, affinity. Rabbits generate antibodies with picomolar-range Kd values — routinely 10–100× higher affinity than typical mouse monoclonal antibodies. This is driven by a dual diversification mechanism: somatic hypermutation (shared with mouse and human) plus somatic gene conversion in the rabbit gut-associated lymphoid tissue, which introduces additional sequence diversity into the rearranged V(D)J genes.

Second, epitope coverage. Rabbit antibodies recognize epitopes that mouse antibodies frequently miss, including small-molecule haptens, post-translational modifications, and conserved protein surfaces. The longer rabbit CDR3 regions — particularly CDRH3 — contribute to broader paratope diversity and better penetration into surface crevices on antigens.

Third, structural simplicity. Rabbit IgG has a single IgG subclass with a conserved hinge region, simpler than the multi-subclass systems of mouse and human. This simplifies recombinant expression and reduces the need for subclass screening during lead selection.

The irony — and the reason scBCR-seq matters for rabbit work — is that the very species with the most desirable antibody properties has been the hardest to work with using traditional methods. Single-cell BCR sequencing removes the fusion bottleneck entirely, letting rabbit B-cell biology deliver what it is capable of: high-affinity, high-specificity antibodies with native pairing intact.

From Spleen to Validated Antibody in One Week

Figure 2. Funnel diagram of the Huang et al. 2026 case study — from single-cell BCR capture to functional antibody validation in one week.

The Huang et al. 2026 study, published in Microchemical Journal, provides the clearest published demonstration of scBCR-seq for rabbit monoclonal antibody development. The target was monensin, a polyether ionophore antibiotic used in livestock that leaves residues in beef and milk. The detection challenge is typical for small-molecule food safety applications: the analyte is too small (~671 Da) for sandwich immunoassays, and detection requires a high-affinity, high-specificity antibody that discriminates monensin from structurally related ionophores.

The team immunized New Zealand White rabbits with a monensin-BSA conjugate. After the final boost, splenocytes were harvested and monensin-specific memory B cells were enriched by FACS using fluorescently labeled monensin-BSA. The enriched cells were processed on a microfluidic single-cell platform for rabbit BCR sequencing.

The numbers tell the story:

• 5,540 cells captured in the scBCR-seq run
• 2,696 cells (48.7%) yielded high-quality paired heavy- and light-chain sequences
• 15 candidate sequences selected for recombinant expression, prioritized by clonal abundance, somatic hypermutation (SHM) rate, and CDR3 clustering
• 12 of 15 (80%) produced functional, antigen-binding rabbit monoclonal antibodies upon recombinant expression
• Lead candidate T40 showed the strongest binding signal and was advanced to full characterization

The team subjected T40 to molecular dynamics simulation, which demonstrated structural stability across a range of salt concentrations and pH conditions — important for an antibody intended for field-deployable detection in complex sample matrices. The time-resolved fluorescence immunoassay (TRFIA) built on T40 achieved a limit of detection of 0.22–0.53 ng/g in bovine tissue and milk, with recovery rates of 88.1%–107.1% and coefficients of variation below 15%. Total detection time was under 10 minutes, compared to approximately 45 minutes for commercial ELISA kits.

This is the practical value proposition of scBCR-seq: a single experiment, completed in about a week from sorting to expression, produced 12 validated antibodies — any of which could serve as the recognition element for a diagnostic assay.

The timeline described here reflects the specific conditions of the Huang et al. study. Actual project timelines vary depending on immunization schedules, sample availability, single-cell platform choice, expression vector construction, and validation requirements. For a timeline estimate tailored to your antibody discovery project, please contact CD Genomics directly.

Where scBCR-seq Outperforms Traditional Methods

The comparison between scBCR-seq and older antibody discovery approaches is not theoretical — it has been quantified. Goldstein et al. 2019 benchmarked scBCR-seq against hybridoma from the same immunized rat splenocyte pool. scBCR-seq recovered 81% (56/69) of the B-cell lineages that hybridomas identified. More importantly, it identified 710 additional candidate lineages that hybridoma screening missed entirely. Of 93 synthesized and expressed scBCR-seq-derived clones, 92 (99%) were antigen-reactive by ELISA and surface plasmon resonance, with a median KD of 3.5 nM and a range from sub-10 pM to 30 nM.

Why does scBCR-seq find more clones? Three mechanisms contribute:

• No fusion efficiency bottleneck. Hybridoma cell lines require successful myeloma–B-cell fusion, a stochastic process with efficiency measured in thousandths of a percent. scBCR-seq captures every sorted B cell equally.
• No clonal competition. In hybridoma culture, faster-growing clones can dominate wells and obscure slower-growing but higher-affinity clones. scBCR-seq reads every cell independently.
• No species restriction. The method works on mouse, rat, rabbit, and human B cells without modification. There is no species-matched fusion partner to develop, no species-specific selection markers to optimize.

Phage display remains the method of choice when the goal is to screen extremely large diversity libraries (10⁸–10¹⁰ variants) against a panel of targets, or when immunized animals are not available. But for projects where an immunized host — particularly rabbit — is available, scBCR-seq now provides the most direct path from B cell to validated antibody.

Planning Your Antibody Discovery Project

Figure 3. Single-cell BCR sequencing vs. traditional antibody discovery methods — timeline, throughput, and success rate comparison.

Building a scBCR-seq-based antibody discovery project involves decisions at several stages. The following framework is based on published workflows and the practical experience documented in the Huang et al. 2026 and Goldstein et al. 2019 studies.

Immunization and sampling strategy. The quality of the starting B-cell population determines the quality of the output. Standard multi-dose immunization protocols over 6–8 weeks with a final boost 3–5 days before sample collection produce the strongest antigen-specific memory B-cell and plasmablast responses. For rabbit work, spleen is the preferred tissue source because it yields the highest number of B cells. Peripheral blood is an alternative when splenectomy is not feasible, though B-cell numbers will be lower and may require larger blood volumes.

Enrichment strategy. For defined protein or peptide antigens, FACS-based enrichment using fluorescently labeled antigen provides the highest specificity — antigen-binding cells can be gated directly. For small-molecule haptens (as in the Huang et al. study), a hapten-carrier conjugate labeled with a distinct fluorophore can be used, with counter-screening against the carrier protein alone to exclude carrier-specific clones. For membrane protein targets, fluorescently labeled recombinant protein or antigen-overexpressing cells can serve as sorting reagents.

Sequencing platform choice. Most scBCR-seq platforms are compatible with rabbit B cells, but 5′ barcoding chemistry is required to capture the full V(D)J region including the CDR3. Droplet-based platforms (e.g., 10x Genomics) and microwell-based platforms (e.g., BD Rhapsody) both support BCR enrichment and paired-chain recovery. The key check is whether the platform's BCR enrichment primers cover rabbit V-gene segments — commercial rabbit BCR kits are now available from multiple providers.

Candidate selection logic. After sequencing, selecting which VH-VL pairs to synthesize and express involves several prioritization criteria: clonal abundance (highly expanded clones are more likely to be antigen-driven), SHM rate (higher mutation load correlates with affinity maturation), CDR3 length and charge (longer CDR3 regions with balanced hydrophobicity are favorable for rabbit antibodies), and clonal family clustering (multiple members of the same clonal lineage with shared V(D)J rearrangements provide independent validation of the lineage).

Validation strategy. The 80% screening success rate reported by Huang et al. was achieved with a straightforward ELISA-based binding screen against the target antigen, followed by a competitive ELISA to confirm specificity. For therapeutic applications, additional biophysical characterization — SPR or BLI for affinity measurement, SEC for aggregation assessment, and thermal stability testing — is standard.

For researchers considering scBCR-seq as part of an antibody discovery program, the CD Genomics Single-cell Immune Repertoire Sequencing service provides paired-chain BCR and TCR analysis across multiple species, including rabbit, mouse, and human, alongside integrated single-cell transcriptomics and multi-omics workflows.

FAQ

Q: How does scBCR-seq compare to phage display for antibody discovery?
scBCR-seq preserves native heavy-light chain pairing — the VH and VL sequences come from the same B cell. Phage display creates artificial pairings during library construction, which means a high-affinity phage clone may represent a combination that never existed in vivo. For projects where an immunized host is available, scBCR-seq provides a more direct route to functional antibodies with pairing fidelity that phage display cannot match. Phage display remains the better choice when immunized animals are not available or when the goal is to screen extremely large diversity libraries (10⁸–10¹⁰ variants) against multiple targets.

Q: What species can be used for scBCR-seq antibody discovery?
scBCR-seq has been validated in mouse, rat, rabbit, and human B cells. The method is inherently species-agnostic because it relies on poly(A) mRNA capture rather than species-specific probes. The practical limitation is the availability of V-gene reference databases and BCR enrichment primer sets — both of which are now commercially available for the major research species.

Q: How many B cells do I need for a successful scBCR-seq antibody discovery run?
For a typical scBCR-seq experiment, 2,000–5,000 enriched antigen-specific B cells is a practical target. At a 50% paired-chain recovery rate, this yields 1,000–2,500 paired VH-VL sequences. If the starting splenocyte population contains 0.5–2% antigen-specific memory B cells (typical for a well-immunized animal), FACS enrichment from 10⁶–10⁷ total splenocytes is usually sufficient to reach this target.

Q: Can scBCR-seq be combined with single-cell transcriptome analysis?
Yes. Many scBCR-seq platforms support simultaneous 5′ gene expression and V(D)J enrichment from the same single cell. This enables integrated analysis of B-cell transcriptional state, clonal expansion, and antibody sequence — useful for understanding the relationship between B-cell phenotype and antibody properties, and for identifying the transcriptional programs associated with high-affinity clones.

Q: What is the biggest risk factor for a failed scBCR-seq antibody discovery project?
The quality of the starting B-cell population. Poor immunization, insufficient antigen-specific enrichment, or low cell viability after sorting all reduce the number of paired VH-VL sequences recovered and, more importantly, reduce the likelihood that high-affinity clones are represented in the sequenced population. A well-designed immunization protocol — multi-dose, with a final boost timed correctly — and careful FACS gating on antigen-binding, IgG-positive cells are the highest-return investments in project success.

References

1. Huang J, Qing Y, Ma X, Lin A, Li J. Rapid detection of monensin via time-resolved fluorescence immunoassay based on rabbit monoclonal antibodies from single-cell BCR sequencing. Microchemical Journal. 2026;225:118187.
2. Goldstein LD, Chen YJ, Wu J, et al. Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies. Communications Biology. 2019;2:304.
3. Kuai M, Shi Z, Li B, et al. Rabbit monoclonal antibodies: Synergistic innovation and breakthrough based on B-cell development mechanism and single B-cell technology. Colloids and Surfaces B: Biointerfaces. 2025;257:115179.
4. Schardt JS, Sivaneri NS, Tessier PM. Monoclonal antibody generation using single B cell screening for treating infectious diseases. BioDrugs. 2024;38(4):477-486.
5. Gérard A, Woolfe A, Mottet G, et al. High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nature Biotechnology. 2020;38(6):715-721.

Research Use Only Statement

The information provided in this article is for research use only and is not intended for use in diagnostic or therapeutic procedures. CD Genomics provides sequencing and bioinformatics services for research purposes. Researchers should consult the appropriate regulatory guidelines for their specific applications.